title: Management of serious adverse drug reactions: proposals from a victims' organisation.
abstract: Amalyste is a French patient-advocacy group for victims of two very serious adverse drug reactions: Lyell and Stevens-Johnson syndromes. The aims of this organisation are to represent the interests of patients who have experienced these syndromes; to better inform the public about these syndromes; to provide analyses of drug-related risks; and to demand collective compensation for victims of serious adverse drug reactions. The following text is our translation of an Amalyste position statement on drug-related risks. It provides valuable food for thought, both for healthcare professionals and for drug regulatory agencies, and has the potential to improve practice (a).
mesh_terms: D035881:Compensation and Redress / Q000331:legislation & jurisprudence; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D005602:France; D033161:Government Regulation; D006291:Health Policy; D006801:Humans; D009939:Organizations, Nonprofit / Q000191:economics / Q000331:legislation & jurisprudence; D010344:Patient Advocacy / Q000191:economics / Q000331:legislation & jurisprudence; D061214:Patient Safety / Q000191:economics / Q000331:legislation & jurisprudence; D018570:Risk Assessment; D012307:Risk Factors; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology / Q000628:therapy*